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Background: The K65R substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is
the major resistance mutation selected in patients treated with first-line antiretroviral tenofovir disoproxil fumarate
(TDF). 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), is the most potent nucleoside analog RT inhibitor (NRTI) that
unlike all approved NRTIs retains a 3'-hydroxyl group and has remarkable potency against wild-type (WT) and drug-
resistant HIVs. EFdA acts primarily as a chain terminator by blocking translocation following its incorporation into
the nascent DNA chain. EFdA is in preclinical development and its effect on clinically relevant drug resistant HIV
strains is critically important for the design of optimal regimens prior to initiation of clinical trials.
Results: Here we report that the K65R RT mutation causes hypersusceptibility to EFdA. Specifically, in single
replication cycle experiments we found that EFdA blocks WT HIV ten times more efficiently than TDF. Under the
same conditions K65R HIV was inhibited over 70 times more efficiently by EFdA than TDF. We determined the
molecular mechanism of this hypersensitivity using enzymatic studies with WT and K65R RT. This substitution
causes minor changes in the efficiency of EFdA incorporation with respect to the natural dATP substrate and also in
the efficiency of RT translocation following incorporation of the inhibitor into the nascent DNA. However, a
significant decrease in the excision efficiency of EFdA-MP from the 3’ primer terminus appears to be the primary
cause of increased susceptibility to the inhibitor. Notably, the effects of the mutation are DNA-sequence dependent.
Conclusion: We have elucidated the mechanism of K65R HIV hypersusceptibility to EFdA. Our findings highlight
the potential of EFdA to improve combination strategies against TDF-resistant HIV-1 strains.
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Human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) is the major target of antiretroviral
drug treatments. RT inhibitors constitute the largest
class of HIV-1 drugs and are grouped in two separate
categories. The first category consists of the nucleos(t)
ide RT inhibitors (NRTIs), which are analogs of the nat-
ural nucleosides. Most NRTIs lack a 3’-OH and act as
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distribution, and reproduction in any medium[1-8]. The other group includes the nonnucleoside RT
inhibitors (NNRTIs), which are non-competitive RT in-
hibitors with respect to either dNTP or nucleic acid sub-
strates and block DNA synthesis by binding to a
hydrophobic pocket of RT [9-15]. Highly Active Anti-
retroviral Therapies (HAART) are based on combina-
tions of antiretrovirals and have helped extend the lives
of HIV-1 patients. However, the efficacy of combination
therapies is being challenged by the selection of drug-
resistant variants of HIV-1.
There are two major mechanisms of NRTI resistance
[16,17]. The first is the discrimination mechanism,
which is based on decreased incorporation of the nu-
cleotide analog into the elongating DNA over the ca-
nonical dNTP substrate [16,18-21]. An example of thistral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 EC50 determination of EFdA and TDF in single
cycle cell-based assays
Virus EC50 ± SD (nM) (Fold change)
EFdA TDF
WT 3.2 ± 0.7 32 ± 6
(1) (1)
K65R 1.3 ± 0.4 96 ± 3
(0.4) (3)
The data show “mean value ± standard deviation” obtained from the results of
at least three independent experiments (P < 0.013). The relative increase in
EC50 values against K65R virus compared with WT virus is given
in parentheses.
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which decreases HIV susceptibility to lamivudine (3TC)
and emtricitabine (FTC) [20-24]. The second mechan-
ism is the excision mechanism, which is based on the
enhanced ability of the mutant RT to remove the chain-
terminating inhibitor from the DNA terminus [25-28]
through a phosphorolytic reaction that uses primarily
adenosine triphosphate (ATP) as a substrate. Upon re-
moval of the inhibitor DNA synthesis resumes. The ex-
cision reaction is facilitated by Excision Enhancement
Mutations (EEMs), typically M41L, D67N, K70R,
T215Y/F, L210W, and K219E/Q, which are also known
as Thymidine Associated Mutations (TAMs) because
they were historically linked to resistance to thymidine
analogs AZT and d4T [29,30].
Tenofovir disoproxil fumarate (TDF) is one of the
most prescribed anti-HIV drugs, and is described as a key
component of all first-line regimens in the DHHS HIV
guidelines (http://aidsinfo.nih.gov/contentfiles/lvguidelines/
adultandadolescentgl.pdf). The K65R mutation in HIV-1
RT is the signature mutation selected during tenofovir-
based therapy. Viruses carrying K65R have reduced sus-
ceptibility to tenofovir and other NRTIs, but remain
susceptible to zidovudine (AZT) [31-36]. This mutation
has also been associated with a reduction in viral repli-
cation capacity, NRTI excision, NRTI incorporation,
and dNTP incorporation [37-43]. Recent crystallo-
graphic data suggest that the K65R mutation disrupts
the interaction between the side chains of 65R and 72R
resulting in structural changes that lead to NRTI resist-
ance [44].
We have previously shown that a series of NRTIs with
4’-substitutions and a 3’-OH group are very potent inhibi-
tors of WT and multi-drug resistant HIV-1. The most
effective of these compounds is the adenosine analog 4’-
ethynyl-2-fluoro-2’-deoxyadenosine (EFdA) [45,46]. We
have demonstrated that EFdA acts in a DNA-sequence
specific manner, primarily inhibiting DNA synthesis as
an immediate chain terminator, but less often, at some
DNA sequences can also act as a delayed chain termin-
ator [46]. Compounds that exhibit this novel mechanism
of inhibition have been dubbed Translocation Defective
Reverse Transcriptase Inhibitors (TDRTIs) [46].
In an effort to investigate the effect of EFdA against
drug-resistant strains of HIV-1 we found that RT mu-
tation K65R confers hypersusceptibility to EFdA. We
carried out a series of biochemical experiments to
elucidate the mechanism of this phenomenon and we
propose here that K65R increases the susceptibility
to EFdA mainly by suppressing the ATP- or PPi-
dependent repair of EFdA-MP-terminated DNA.
Understanding the molecular basis of K65R hyper-
susceptibility to EFdA may lead to new and more effect-
ive combination therapies.Results
The K65R RT mutation enhances susceptibility of HIV to
EFdA
In order to determine the susceptibility of HIV-1 to
EFdA we performed single infectivity viral replication as-
says according to the experimental procedures described
in Methods section. We used as a positive control of re-
sistance to K65R HIV-1 the nucleotide analog TDF.
Table 1 shows that K65R-containing viruses are at least
2.5-fold more susceptible to EFdA than WT viruses. In
contrast, there was a 3-fold resistance to tenofovir
caused by K65R RT mutation.
The K65R mutation enhances susceptibility of RT to
EFdA-TP
In order to recapitulate the HIV hypersusceptibility to
EFdA observed in cell-based assays and determine the
biochemical mechanism of this phenomenon we carried
out a series of biochemical experiments. We used a pri-
mer extension assay to compare the effect of EFdA-TP
on DNA-dependent DNA polymerization by WT and
K65R RTs. In order to assess the effect of ATP-based ex-
cision on the susceptibility of RT to EFdA-TP we
performed the reactions in the absence (Figure 1A) and
in the presence of ATP (Figure 1B). In the absence of
ATP, any changes in the susceptibility to the inhibitor
would be caused by the “decreased incorporation” mech-
anism as there are no NRTI excision events under these
conditions. However, changes in inhibitor susceptibility
in the presence of ATP could be caused either by
“changes in inhibitor incorporation” or “changes in in-
hibitor excision”, or both. Figure 1 and Table 2 show
that RT mutation K65R causes hypersusceptibility to
EFdA-TP. In the presence of ATP the K65R mutation
caused a 2.5-fold increase in susceptibility to EFdA-TP
(Table 2). These data are consistent with the results
from the cell-based assays shown in Table 1. The ~2-fold
effect of ATP-based excision on the hypersusceptibility
to EFdA suggests that excision is the major mechanism
of this phenomenon and is further characterized in the
subsequent experiments.
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Primer extension assay in the presence of EFdA-TP
Figure 1 Inhibition of WT and K65R RT-catalyzed DNA synthesis by EFdA-TP. Td31/Pd18-P0 was incubated with WT or K65R HIV-1 RT for
50 minutes in the presence of 1 μM dNTPs, MgCl2 and increasing concentrations of EFdA-TP (0–1,500 nM). The experiment was carried out in the
(A) absence or (B) presence of 3.5 mM ATP. The template sequence is shown next to the gels and the numbers indicate the points of EFdA-TP
incorporation (+1, +6 and +10).
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corporation of dATP analogs opposite template dTs at
positions “1”, “6” and “10” (Figure 1). The stopping pat-
tern of the gels showed that EFdA-TP caused major
pauses at all possible points of incorporation (positions
1, 6 and 10), suggesting that EFdA-TP inhibits RT
mainly as an immediate chain terminator at the point of
incorporation. Interestingly, EFdA-TP caused an add-
itional strong stop of WT RT at position “+7”, which is
one nucleotide after its incorporation (Figure 1), thereby
acting as delayed chain terminator at this site. Hence,
this appears to be a sequence-dependent phenomenon,
as we did not observe delayed chain extension at posi-
tions +2 and +11 and there was no pause at this site in
the absence of inhibitor (Figure 1).
The K65R RT mutation does not enhance susceptibility to
EFdA by significantly affecting incorporation of the
inhibitor
To determine the biochemical mechanism of increased
K65R HIV inhibition by EFdA we examined severalTable 2 Enhancement of hypersusceptibility to EFdA-TP unde
Enzyme IC50 (nM) of EFdA-TP ± SD (Fold change)
Without ATP With 3.5 mM ATP
WT RT 186 ± 40a (1)b 318 ± 99a (1)b
K65R RT 125 ± 28a (0.7)b 131 ± 28a (0.4)b
aThe data show “mean value ± standard deviation” obtained from the results of at l
bThe relative increase in IC50 value in K65R RT compared with WT RT without, or wi
cThe effect of ATP-based excision on hypersusceptibility is calculated by the relative
in IC50 for K65R compared to WT RT with ATP.possible mechanisms. The first hypothesis was that the
K65R RT mutation selectively enhances incorporation of
the EFdA-TP inhibitor into DNA because of changes in
kinetic parameters such as binding or turnover rate of in-
hibitor incorporation. To evaluate this hypothesis we
performed single nucleotide incorporation assays under
steady state conditions. In order to eliminate a sequence-
dependent bias we used three different template/primers
(T/P) (Td26/Pd18-P5, Td31/Pd18-P0, and Td31A/Pd21 [Table 3]).
Our results showed that under these conditions the ratio
of the incorporation efficiency (kcat/Km) of EFdA-TP and
the incorporation efficiency of dATP by K65R RT was be-
tween 0.8 and 1. These results suggest that the K65R mu-
tation does not have a significant effect on the binding
and incorporation of EFdA-TP (Table 4).
The K65R RT mutation does not enhance susceptibility to
EFdA by significantly affecting enzyme translocation on
EFdA-MP-terminated template/primers
We have previously shown that the inability of RT to form
a stable ternary complex with T/PEFdA-MP and the nextr ATP-based excision conditions
Hypersusceptibility enhancement in the presence of ATP
1c
1.8c
east four independent experiments (P < 0.011).
th ATP is given in parentheses.
change in IC50 for K65R compared to WT RT without ATP/the relative change
Table 3 Sequences of oligonucleotides used in this study
Polymerization
assays
Td31 5’CCA TAG ATA GCA TTG GTG CTC GAA CAG TGA C
Pd18-P0 5’Cy3 GTC ACT GTT CGA GCA CCA
Td26 5’CCA TAG ATA GCA TTG GTG CTC GAA CA
Pd18-P5 5’Cy3 TGT TCG AGC ACC AAT GCT
Td31A 5’AAA AAA AAA TGG ATA CAT ATG GTT AAA GTA T
Pd21 5’Cy3 ATA CTT TAA CCA TAT GTA TCC
Footprinting
assays
Td43 5’Cy3 CCA TAG ATA GCA T TG GTG CTC GAA CAG
TGA CAA TCA GTG TAG A
Pd30 5’TCT ACA CTG ATT GTC ACT GTT CGA GCA CCA
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minal EFdA-MP primer to efficiently translocate from the
nucleotide binding site (N site, which is also the pre-
translocation site) to the post-translocation primer site (P
site or the post-translocation site) [46]. Hence, another pos-
sible mechanism by which the K65R mutation could en-
hance susceptibility to EFdA is by further suppressing
translocation of RT on the EFdA-MP-terminated T/P. To
evaluate this hypothesis we used the site-specific Fe2+ foot-
printing assay [46,47] to assess the translocation state of
WT and K65R RT·T/PEFdA-MP complexes in the absence,
and in the presence of varying concentrations of the next
incoming dNTP. Figure 2 shows that EFdA-TP blocked
translocation and acted as a strong TDRTI against both
WT and K65R RTs. At physiological dNTP concentrationsTable 4 Steady state kinetic parameters for EFdA-TP and dAT
Enzyme dNTP Km (μM) kcat (min
-1)
Td26/Pd18-P5
WT RT dATP 2.38 ± 0.27 1.58 ± 0.12
EFdA-TP 0.66 ± 0.04 3.26 ± 0.42
K65R RT dATP 5.99 ± 0.81 0.92 ± 0.14
EFdA-TP 1.83 ± 0.34 1.74 ± 0.42
Td31/Pd18-P0
WT RT dATP 0.33 ± 0.07 6.32 ± 0.14
EFdA-TP 0.23 ± 0.01 4.73 ± 0.33
K65R RT dATP 0.42 ± 0.01 3.62 ± 0.71
EFdA-TP 0.31 ± 0.02 3.07 ± 0.15
Td31A/Pd21
WT RT dATP 0.37 ± 0.08 3.64 ± 0.57
EFdA-TP 0.19 ± 0.06 3.54 ± 0.44
K65R RT dATP 1.06 ± 0.11 3.68 ± 0.28
EFdA-TP 0.53 ± 0.05 3.38 ± 0.29
Values are mean ± S.D. of two to four independent experiments and were determin
aSelectivity is the ratio of the incorporation efficiency (kcat/Km) of EFdA-TP over that
bFold Change is the ratio of the selectivity in K65R over the selectivity in WT RT.(1-25 μM) we observed a 1.5-fold decrease in the transloca-
tion efficiency of K65R compared to WT RT under these
conditions. To determine whether the lower amount of ob-
served translocated K65R RT·T/PEFdA-MP complex (Figure 2)
is due to a decreased affinity of K65R RT for EFdA-MP-ter-
minated T/P we studied the effect of K65R on the forma-
tion of RT·T/PEFdA-MP binary complex using gel-shift
assays. Data in Additional file 1: Figure S1 show that WT
RT binds EFdA-MP-terminated T/P only slightly stronger
than K65R RT (~1.3-fold). Therefore, the small differences
in the selectivity, translocation activity, and DNA binding of
WT and K65R RTs were not sufficient to explain the
hypersusceptibility we observed in cell-based and RT assays
with EFdA and EFdA-TP respectively. Therefore, in the fol-
lowing experiments we examined whether the K65R substi-
tution could enhance susceptibility to EFdA by suppressing
the ability of RT to unblock EFdA-MP-terminated primers.
ATP- and PPi-dependent Excision/Rescue of EFdA-MP
We have previously demonstrated that using simple
pyrophosphorolysis reactions (in the absence of concurrent
DNA polymerization) is not an effective way to monitor
unblocking of EFdA-MP-terminated primers. This is because
the net phosphorolysis is limited from the apparently facile
reincorporation of the newly excised EFdA-TP [46]. Hence,
to better study the potential role of the excision mechanism
in EFdA resistance we employed rescue assays, where in
addition to the ATP or PPi which are used as unblocking re-
agents, we also include dNTPs that compete with and pre-
vent reincorporation of EFdA-TP, and also allow further
DNA synthesis. For these experiments we used as a substrateP incorporation by WT and K65R HIV-1 RTs
kcat / Km (min
-1 · μM-1) Selectivitya Fold changeb
0.66 1 1
4.94 7.5
0.15 1 0.8
0.95 6.3
19.15 1 1
20.57 1.1
8.62 1 1
9.90 1.1
9.84 1 1
18.63 1.9
3.47 1 0.9
6.38 1.8
ed from Michaelis-Menten equation using GraphPad Prism 4.
of dATP ([kcat/Km]EFdA-TP / [kcat/Km]dATP).
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Figure 2 Effect of K65R mutation on the translocation state of RT bound to T/PEFdA-MP. (A) The translocation state of HIV-1 RT after EFdA-
MP incorporation was determined using site-specific Fe2+ footprinting. Td43/Pd30-EFdA-MP (100 nM) with 5'-Cy3-label on the DNA template was
incubated with WT or K65R HIV-1 RT (600 nM) and various concentrations of the next incoming nucleotide (dTTP). The complexes were treated
for 5 minutes with ammonium iron sulphate (1 mM) and resolved on a polyacrylamide 7 M urea gel. An excision at position −18 indicates a pre-
translocation complex, while the one at position −17 represents a post-translocation complex. (B) The post-translocated complexes were
determined from the gels and plotted using GraphPad Prism. Light blue indicates the physiological dNTP concentrations. (C) Schematic
representation of the position of EFdA-MP-terminated primers at the pre- and post-translocated sites.
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(Td31/Pd18-P0-EFdA-MP). Using ATP as the pyrophosphate
donor, we found that the initial rates of the rescue reactions
were 2.8-fold slower by K65R than by WT RT (Figure 3A).
A 6.5-fold decrease was also observed in PPi-based rescue
(Figure 3B). As previously reported [48] the PPi-rescue was
faster than the ATP-based rescue assay. Whereas the PPi-
based hydrolysis is exactly the opposite of DNA synthesis in
reverse, ATP-based hydrolysis has some differences, as we
have also structurally demonstrated in the crystal structure
of RT in complex with DNA and tetraphosphate excisionproduct [49]. The above experiments provide strong evi-
dence that K65R mutation confers hypersusceptibility to
EFdA mainly through decreased excision.
Discussion
Tenofovir is a major component of current antiviral therap-
ies (http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultand
adolescentgl.pdf) and new HIV drugs are likely to be used in
patients that have failed tenofovir-based treatment. Hence,
the ability of novel HIV inhibitors to efficiently block
tenofovir-resistant viruses is critical for their potential utility
Time (min)
0 1 2 3 5 10 20 30 40
WT RT
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Time (min)
0 1 2 3 5 10 20 30 40
K65R RT
B
T/PEFdA-MP
PPi-dependent rescue of T/PEFdA-MP
Time (min)
WT RT
Rescued
Time (min)
K65R RT
A
T/PEFdA-MP
ATP-dependent rescue of T/PEFdA-MP
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5
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5
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Figure 3 ATP- and PPi-dependent rescue of EFdA-MP terminated primers by WT and K65R RTs. (A) ATP-dependent rescue of
Td31/Pd18-P0-EFdA-MP. Purified Td31/Pd18-P0-EFdA-MP was incubated with WT or K65R RT in the presence of 10 mM MgCl2, 3.5 mM ATP, 100 μM dATP,
0.5 μM dTTP, and 10 μM ddGTP at 37°C. Aliquots of the reaction were stopped at the indicated time points (0–90 min). The results of at four
independent experiments were plotted using one site hyperbola in Graphpad Prism 4. (B) PPi-dependent rescue of Td31/Pd18-P0-EFdA-MP. Purified
Td31/Pd18-P0-EFdA-MP was incubated with WT or K65R RT in the presence of 6 mM MgCl2, 150 μM PPi, 100 μM dATP, 0.5 μM dTTP, and 10 μM
ddGTP at 37°C. Aliquots of the reaction were stopped at the indicated time points (0–40 min). The results of two independent experiments were
plotted using one site hyperbola in Graphpad Prism 4.
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ance is defined as a 2.1-fold reduction in virological response.
It is associated with the presence of the tenofovir-resistance
signature mutation K65R in the reverse transcriptase gene[50]. We report here that EFdA is highly potent against
tenofovir-resistant K65R HIV, and inhibits this mutant 2.5-
fold more efficiently than WT HIV. Given the fact that clin-
ical resistance to tenofovir is considered a 2.1-fold decrease
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ity as significant hypersusceptibility. Understanding the
mechanism by which HIV becomes resistant or more sus-
ceptible to EFdA could allow us to overcome drug resistance
challenges and improve the current combination therapies.
We have previously demonstrated that EFdA is highly effi-
cient in suppressing viral replication of clinical isolates har-
boring signature mutations to other NRTIs and NNRTIs,
including isolates containing 3TC/FTC resistance muta-
tion M184V; TAMs or Q151M complex mutations that
confer resistance to AZT, d4T, and abacavir; and nevira-
pine and efavirenz resistance mutations K103N and
Y181C [45]. In addition, we have recently shown that
EFdA is 3 logs more potent in SIV inhibition than
tenofovir, AZT, and 3TC, and EFdA treatment decreases
viral load in SIV-infected macaques by 3–4 logs within
1 week of SIV therapy and eventually to non-detectable
levels [51]. The present study demonstrates that the K65R
tenofovir-resistance RT mutation confers HIV hypersensi-
tivity to EFdA compared to WT HIV. Other studies have
shown that NRTI resistance mutations can confer en-
hanced susceptibility to other NRTIs. Specifically, the
K65R and to a lesser extent the L74V RT mutations have
been reported to suppress AZT resistance [43,52-55]. In
addition, we have previously reported that K65R and
L74V HIVs can be hypersusceptible to NRTIs with 4’-ethy-
nyl substitutions [45,56]. The NNRTI-resistance mutation
Y181C also increases susceptibility to AZT [57,58]. More-
over, the 3TC/FTC-resistance mutation M184V also in-
creases HIV sensitivity to AZT by decreasing the excision
efficiency of AZT-MP [22,53,59-61]. Finally, we have re-
cently shown that the 172K polymorphism can enhance
susceptibility to both NRTIs and NNRTIs [62].
To determine whether the K65R RT mutation has the
same effect at the enzyme level as well, we also carried
out inhibitor susceptibility experiments with WT and
K65R recombinant RT enzymes. Indeed, our enzymatic
assays clearly showed that K65R RT is more susceptible
to inhibition by EFdA-TP than WT RT. We thus focused
on the biochemical mechanism of the enhanced EFdA
susceptibility. We previously reported that EFdA is a
TDRTI and inhibits primarily by blocking translocation
after its incorporation at the 3’-end of the primer
[45,46]. Hence, we investigated the effect of the K65R
mutation on translocation using the site-specific Fe2+
footprinting assay. We found that K65R mutation has
only a small effect on the translocation state of the
EFdA-MP-terminated DNA·RT complex suggesting that
the EFdA-MP-terminated primers stay at the nucleotide
binding site (N site) of K65R RT as much as they do at
the N site of WT RT. Since the EFdA resistance was not
the result of changes in translocation efficiency, we hy-
pothesized that K65R affects either the incorporation of the
inhibitor itself, or its excision from EFdA-terminatedprimers. The effect on incorporation efficiency was assessed
with single nucleotide incorporation experiments, whereas
the effect on excision was measured in PPi- and ATP-
dependent excision experiments under steady state con-
ditions. Our results showed that the K65R mutation
decreased the incorporation efficiencies of EFdA-TP and
dATP to the same extent. Since pyrophosphorolysis is the
reverse reaction of polymerization we hypothesized that it
would also be slower in the presence of this mutation. This
was confirmed by a PPi-based excision assay where we
measured unblocking of EFdA-MP from the 3’-end of the
primer. We found that K65R reduced excision and kept
EFdA-MP-terminated primers blocked, explaining the
hypersusceptibility that we have reported. In addition, when
we used conditions that more closely mimic cell-based con-
ditions, with ATP as the unblocking reagent and also all
dNTPs present in the reaction to extend the unblocked
primers, we also found that K65R reduced excision. Since
the footprinting data did not show any significant difference
in the translocation efficiency we can therefore conclude
that the excision is not decreased because the EFdA-
MP-terminated primers reside less at the excisable site. A
decreased unblocking of EFdA-MP-terminated primers is
not due to their inability to bind at the excisable N site of
K65R RT. Instead, the molecular models in Figure 4 suggest
that residues R65 and K65 interact differently with R72 and
the phosphate moieties of EFdA-TP or dNTP, and thus
may differentially affect the recognition of the pyrophos-
phate donor (ATP or PPi) and its nucleophilic attack on
EFdA-terminated primers. Future crystallographic studies
should provide more details on the molecular basis of
excision-based EFdA resistance.
Conclusion
We have provided virological and biochemical data dem-
onstrating that the K65R RT mutation confers enhanced
sensitivity to EFdA. We reported here that the mechan-
ism of hypersensitivity is mainly through reduced exci-
sion of the chain terminating EFdA-MP. Our findings
demonstrated that EFdA is a very potent NRTI and it
could be used not only against WT HIV but also against
tenofovir-resistant HIVs. The primary resistance muta-
tion for EFdA is M184V and combination with tenofovir
could be similar to the pair of mutations for 3TC/AZT
combination. Unlike AZT and 3TC which are analogs
of different deoxynucleosides, EFdA and tenofovir are
both deoxyadenosine analogs and would theoretically
compete to each other. However, they are activated/
phosphorylated by different pathways [45]. Therefore,
combination of EFdA with tenofovir could help suppress
K65R resistance. This conclusion has significant poten-
tial therapeutic implications. Moreover, EFdA would be
a good candidate in salvage therapies for patients that
fail tenofovir-treatment due to K65R resistance.
Figure 4 Molecular models of dATP and EFdA-TP in the active sites of WT and K65R HIV RT. dATP (yellow sticks, A and C) and EFdA-TP
(cyan sticks, B and D) are shown at the active sites of WT HIV RT, (A and B) or K65R HIV RT (C and D). The fingers and palm subdomains are
shown in blue and red cartoon, respectively. The primer and template strands are shown in dark gray and light gray sticks, respectively.
Figures were made using PyMOL (The PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC).
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Cells and viruses
TZM-bl cells (CCR5 transduced HeLa-CD4/LTR-β-gal and
luciferase cells) were obtained from the AIDS Research and
Reference Reagent Program, the National Institutes of
Health (NIH). 293T and TZM-bl cells were maintained in
Dulbecco’s Modified Eagle Medium supplemented with
10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml
streptomycin, and used for transfection and antiviral assays,
respectively.
K65R RT mutation was introduced by site-directed mu-
tagenesis as described previously [63,64]. Briefly, the de-
sired mutations were introduced into the Xma I - NheI
region (759 bp) of pTZNX1, which encodes nucleotides
Gly-15 to Ala-267 of HIV-1 RT. After mutagenesis, the
XmaI - NheI cassettes were inserted back into pNL101
and confirmed by sequencing. Viral stocks were obtained
by transfection of each molecular clone into 293T cells
using Fugene 6 (Roche, Mannheim, Germany), harvested
and stored at −80°C until use.
Cell-based drug susceptibility assays
Single-replication-cycle drug susceptibility assays were
performed in triplicates using TZM-bl cells. TZM-bl cells
were infected with diluted virus stock at 400,000 relative
light units (RLU) in the presence of increasing concen-
trations of RTIs and cultured for 48 h. The luciferase
marker gene expressions were measured using the Bright-Glo (Promega, WI). Susceptibility to NRTIs was calculated
as the concentration that reduces RLU (infection) by 50%
(50% effective concentration [EC50]). The data were
obtained from the results of at least three independent ex-
periments and the P values were determined using t-test
statistical analysis.
Enzymes and nucleic acids
HIV-1 RTs were expressed in JM-109 (Invitrogen) bac-
teria and purified by nickel affinity chromatography and
monoQ anion exchange chromatography as previously
described [46,65-69]. Oligonucleotides used in this study
were chemically synthesized and purchased from Inte-
grated DNA Technologies (Coralville, IA). Sequences of
the DNA substrates are shown in Table 3. Deoxy-
nucleotide triphosphates and dideoxynucleotide triphos-
phates were purchased from Fermentas (Glen Burnie,
MD). EFdA was synthesized by Yamasa Corporation
(Chiba, Japan) as described before [70]. Using EFdA as
starting material the triphosphate form EFdA-TP was
synthesized by TriLink BioTechnologies (San Diego,
CA). Concentrations of nucleotides and EFdA-TP were
calculated spectrophotometrically on the basis of
absorption at 260 nm and their extinction coefficients.
All nucleotides were treated with inorganic pyro-
phosphatase (Roche Diagnostics) as described previously
[26] to remove traces of PPi contamination that might
interfere with the rescue assay.
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Inhibition of HIV-1 RT-catalyzed DNA Synthesis by EFdA-TP
DNA template was annealed to 5’-Cy3 labeled DNA pri-
mer (3:1 molar ratio) (Td31/Pd18-P0). To monitor primer
extension, the DNA/DNA hybrid (20 nM) was incubated
at 37°C with WT or K65R HIV-1 RT (20 nM) in a buffer
containing 50 mM Tris (pH 7.8) and 50 mM NaCl (RT
buffer). Subsequently, varying amounts of EFdA-TP were
added and the reactions were initiated by the addition of 6
or 10 mM MgCl2 in a final volume of 20 μl. All dNTPs
were present at a final concentration of 1 μM in the pres-
ence or absence of 3.5 mM ATP. The reactions were ter-
minated after 50 minutes by adding equal volume of 100%
formamide containing traces of bromophenol blue. The
products were resolved on 15% polyacrylamide 7 M urea
gels. In this and in subsequent assays the gels were
scanned with a Typhoon FLA 9000 PhosphorImager (GE
Healthcare, NJ). The bands corresponding to fully-
extended product were quantified using Multi Gauge soft-
ware. The results of at least four independent experiments
were plotted as percent full extension using one site-
competition nonlinear regression in GraphPad Prism 4 to
determine the mean and standard deviation of the IC50 for
EFdA-TP.
Steady-state Kinetics
Single nucleotide incorporation of dATP and EFdA-TP by
WT and K65R RTs
Steady-state kinetic parameters Km and kcat for incorp-
oration of EFdA-TP or dATP were determined using
single nucleotide incorporation in gel-based assays
under saturating concentrations of T/P (10-fold excess
over RT). Reactions were carried out in RT buffer,
6 mM MgCl2, 100 nM Td26/Pd18-P5 or Td31/Pd18-P0 or
Td31A/Pd21 (Table 3) and 10 nM WT or K65R HIV-1
RT in a final volume of 20 μl and stopped at indicated
reaction times. The products were resolved and quanti-
fied as described above. Km and kcat were determined
graphically using the Michaelis-Menten equation. Reac-
tions were carried out in two to four independent
experiments to determine the mean and standard devi-
ation values.
Site-specific Fe2+ footprinting assay
Site-specific Fe2+ footprints were monitored on 5'-Cy3-
labeled DNA templates. 100 nM of 5’-Cy3-Td43/Pd30
was incubated with 600 nM WT or K65R HIV-1 RT in
a buffer containing 120 mM sodium cacodylate (pH 7),
20 mM NaCl, 6 mM MgCl2, and 1 μM EFdA-TP, to
allow quantitative chain-termination. Prior to the treat-
ment with Fe2+, complexes were pre-incubated for
7 min with increasing concentrations of the next in-
coming nucleotide (dTTP). The complexes were treated
with ammonium iron sulfate (1 mM) as previouslydescribed [46,47]. This reaction relies on autoxidation
of Fe2+ [71] to create a local concentration of hydroxyl
radicals, which cleave the DNA at the nucleotide closest
to the Fe2+ specifically bound to the RNase H active
site. These experiments were performed at least twice.
ATP- and PPi-dependent excision and rescue of T/PEFdA-MP
ATP-dependent rescue of T/PEFdA-MP
Template/primer with EFdA-MP at the 3’ primer terminus
(T/PEFdA-MP) was prepared by incubating 500 nM Td31/
Pd18-P0 with 1 μM HIV-1 RT in RT buffer and 6 mM
MgCl2. EFdA-TP was added into the reaction and the mix-
ture was incubated at 37°C for 1 h. After incorporation of
EFdA-TP, the T/PEFdA-MP was purified using the QIAquick
nucleotide removal kit (Qiagen, Valencia, CA). Under
these conditions, the extension of T/P to T/PEFdA-MP
was complete. 20 nM of purified Td31/Pd18-P0-EFdA-MP
was incubated with 60 nM WT or K65R HIV-1 RT in
the presence of 3.5 mM ATP, 100 μM dATP, 0.5 μM
dTTP, and 10 μM ddGTP in RT buffer and 10 mM
MgCl2. Aliquots of the reaction were stopped at
different time points (0–90 min). The data from at least
four independent experiments were analyzed using
GraphPad Prism 4.
PPi-dependent rescue of T/PEFdA-MP
20 nM of purified Td31/Pd18-P0-EFdA-MP was incubated at
37°C with 60 nM WT or K65R HIV-1 RT in the pres-
ence of 150 μM PPi, 100 μM dATP, 0.5 μM dTTP, and
10 μM ddGTP in RT buffer and 6 mM MgCl2. Aliquots
of the reaction were stopped at different times (0–
40 min). The data from at least two independent experi-
ments were plotted using GraphPad Prism 4.
Molecular modeling
Molecular models of dATP and EFdA-TP in the active
site of WT HIV RT were made using PDB ID 1 T05 [72]
as a starting model (WT HIV RT in complex with
tenofovir diphosphate). A molecular model of EFdA-TP
in the active site of K65R HIV RT was made using PDB
ID 3JYT [44] as a starting model (K65R HIV RT in com-
plex with dATP). The sketch module of SYBYL (Version
7.3.5, Tripos International, St. Louis, MO) was used to
make dATP and EFdA-TP molecules. dATP and EFdA-
TP were each superposed to tenofovir diphosphate in
the WT complex, after which the tenofovir diphosphate
was removed. Gasteiger-Huckel charges were calculated
and molecular minimization of the WT-dATP and WT-
EFdA-TP were performed in SYBYL using the Powell
method. SYBYL was also used to add the 2-fluoro and
4’-ethynyl groups to dATP in the K65R complex.
Gasteiger-Huckel charges were then calculated and mo-
lecular minimization was performed as for the WT
complexes.
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Additional file 1: Figure S1. Effect of K65R mutation on the formation
of RT:T/PEFdA-MP complex. Purified T/PEFdA-MP (25 nM) was incubated at
room temperature for 10 min with different concentrations of WT or
K65R RTs in RT buffer and 6 mM MgCl2. RT was used at different
concentrations to obtain RT:DNA ratios that ranged from 0 to 10. Four μl
of 20% sucrose was added to each mixture in a final volume of 24 μl.
The complexes were subsequently resolved on a native 6%
polyacrylamide Tris borate gel and visualized as described in Methods.
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